Articles tagged with Vaccine Introduction
A new white paper by biostatistician Professor Jeffrey S. Morris analyzes the multicomponent US vaccine safety monitoring system, including VAERS and other components. The study suggests improvements to enhance the system's effectiveness and sustain a robust safety monitoring infrastructure.
Researchers have demonstrated a novel vaccine delivery method using dental floss, which stimulates the production of antibodies in mucosal surfaces, such as the lining of the nose and lungs. This technique has shown superior antibody response compared to current oral vaccination methods.
A study by researchers at the University of Arizona Health Sciences found that vaccinated people generated an overall protective immune response to Delta and Omicron strains, with slightly fewer antibodies for the mutated parts of the virus. The research suggests that immune changes due to antigenic imprinting may not be a significant ...
MIT researchers develop polymer microparticles that release vaccine doses at predetermined times after injection, reducing the need for follow-up shots. The particles showed comparable antibody levels to traditional vaccines in mice, paving the way for potential childhood vaccines with fewer doses.
A cross-sectional study found substantial burden of RSV-related hospitalizations, ICU admissions, and deaths in US adults. Increasing RSV vaccination among older adults has the potential to reduce these outcomes.
A new study aims to improve vaccination rates and create new strategies to break down barriers to vaccination in populations with limited access to healthcare. The research team will develop a multilevel intervention strategy to increase vaccine uptake among adults, adolescents, families, and communities.
A recent study has confirmed the efficacy and safety of the dengue vaccine TAK-003, which reduces the risk of contracting the disease by over 50%. The vaccine has shown a high safety profile, with more than 90% of adults and children developing antibodies after administration.
A new analysis reveals that national-level data on rubella vaccination may overlook nuances at the local level, affecting vaccination efforts. Introducing a vaccine program can reduce CRS cases by thousands in the first five years.
A new study finds that the high burden of typhoid fever in sub-Saharan African countries calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines. The study estimates that there are 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths.
A new vaccine patch has delivered an effective immune response to Zika virus in mice, providing rapid protection against the disease. The patch, which uses a high-density microarray platform, targets a specific protein crucial to the virus's survival and evokes T-cell responses up to 270% higher than traditional vaccines.
Bio-TCV, a typhoid conjugate vaccine developed by IVI and Bio Farma, has been licensed in Indonesia following marketing approval from BPOM. The vaccine is expected to provide protection against typhoid fever as early as 9 months of age.
A national US study found trust in government cancer information plummeted by 53% among non-Hispanic Black people during the pandemic. Meanwhile, trust in doctors remained high, highlighting the need for effective communication and access to healthcare services.
A global study aims to better understand the burden of Human papillomavirus (HPV) among girls and women in low- and lower middle-income countries. The study will inform effective strategies to prevent infection and introduce HPV vaccine into national programs, protecting the health of girls and women and reducing rates of cervical cancer.
A recent study found that anxiety about contracting COVID-19 is a significant predictor of vaccine hesitancy. However, proactive coping, a trait involving future planning, also plays a surprising role in vaccine hesitation, amplifying it at both ends of the spectrum.
A study of 57,460 US cases found a sustained decrease in infant pertussis incidence following Tdap vaccine introduction. Maternal vaccination is associated with reduced disease burden among young infants.
A quality improvement program increased pneumococcal vaccination rates from 53% to 70% in adults aged 18-64 years with stage 4 and 5 chronic kidney disease. The intervention, which utilized electronic best practice alerts within the electronic medical record, improved vaccination rates primarily among this high-risk group.
A study found that over 60% of parents of children with kidney disease or hypertension are unsure or unwilling to vaccinate their child against COVID-19. Effective vaccines exist to protect children from COVID-19, and the findings highlight the need for clear communication to address parental concerns.
Two projects aim to vaccinate 40,000 and 60,000 people in Ethiopia against cholera, using the OCV vaccine developed by IVI. The mass vaccination campaign will also establish a disease monitoring system to strengthen local public health capabilities.
A study across eight European countries found that conventional vaccination campaign messages are ineffective due to factors like low health literacy and conspiracy theories. The research suggests a need for targeted messaging strategies tailored to specific groups and communication channels.
A University of Ottawa group is conducting research to equip healthcare professionals with resources to aid patients in French-speaking minority settings make informed decisions about COVID-19 vaccines. The project aims to address language barriers and combat patient disinformation.
A modelling study suggests COVID-19 certification increases vaccine uptake in countries with below-average vaccination coverage. In six countries, certification was linked to a significant uptick in anticipation of restrictions and continued increases after introduction.
A breakthrough oral vaccine candidate has been developed to prevent hookworm infection, which affects half a billion people worldwide. The vaccine triggers a strong immune response and reduces worm numbers by up to 94% in mice trials.
The Fiji national vaccine program against pneumonia and rotavirus has reduced morbidity and mortality among children in the country. Morbidity rates for rotavirus diarrhoea fell by 87% in under-fives, while hospital admissions decreased, resulting in a 39% drop in mortality for young children.
A new international consortium, led by Dr. Kathy Neuzil of the University of Maryland School of Medicine, aims to introduce the typhoid conjugate vaccine in sub-Saharan Africa and Asia. The research highlights challenges such as surveillance, antibiotic resistance, and cost-effectiveness.
A new data visualization platform, VIEW-hub, reveals stark numbers on where shortfalls exist in vaccine introduction and coverage. Globally, 72% of child deaths from pneumonia and diarrhea occur in just 15 countries, with India and Nigeria being the worst-affected. The platform provides real-time data updates to monitor introduction an...
A University of Pittsburgh study found that introducing new vaccines can decrease vaccine availability by up to two-thirds due to storage and transportation issues. Computational models can forecast the impact of new vaccine introduction and identify potential disruptions.
The introduction of a new vaccine, MenAfriVac, has led to a dramatic fall in cases of meningitis A in Burkina Faso, Mali, and Niger. The vaccine, which costs less than $0.50 per dose, is highly effective and protects children as young as one.
A three-dose pneumococcal vaccination program has shown a 70% reduction in serious infections among young children in Norway. The vaccine protects against seven serotypes of pneumococcus, responsible for 70% of severe cases.
By the end of 2006, all countries in the Americas had included Hib vaccine in their immunization schedule. However, efforts are still needed to strengthen invasive bacterial disease surveillance and improve vaccination coverage. The successful introduction of Hib and pneumococcal vaccines could reduce global severe pneumonia burden by ...
A study published in the Archives of Disease in Childhood found that the Men C vaccine is safe for infants, with minimal adverse events reported. The vaccine was administered to almost 3000 infants between 2-5 months old and showed no serious adverse events, with only mild side effects such as swelling and redness at the injection site.